Selective slowing of proximal colon transit in irritable bowel syndrome by the cholecystokinin-receptor antagonist, loxiglumide

Objective: Assessment of the effect of the cholecystokinin-receptor antagonist, loxiglumide, on proximal colon transit in normal subjects and in patients with irritable bowel syndrome. Design: A randomized, placebo-controlled, double-blind crossover study of loxiglumide 800 mg three times daily in which proximal colon transit was assessed using a non-invasive scintigraphic technique. Participants: The study included 10 patients diagnosed with irritable bowel syndrome who were recruited from a gastroenterology outpatient clinic and 11 normal volunteers recruited from staff and students. Intervention: Loxiglumide 800 mg or placebo three times daily for 3 days with an 11-day washout period between treatments